Template:Amiodarone adverse effects: Difference between revisions
GregArmani (talk | contribs) (Created page with "*Bradycardia *Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. *Prolonged QT *Thyrotoxicosis<ref>Rosen's 8th Edition</ref> **...") |
GregArmani (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
*Bradycardia | *[[Bradycardia]] | ||
*Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. | *Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation. | ||
*[[Prolonged QT]] | *[[Prolonged QT]] | ||
Revision as of 13:01, 5 January 2016
- Bradycardia
- Hypotension with older solvent-based formulation. Uncommon with newer aqueous formulation.
- Prolonged QT
- Thyrotoxicosis[1]
- Between 5-20% of patients treated with amiodarone have thyrotoxicosis (higher in areas of iodine deficiency)
- Iodine-induced hyperthyroidism
- It is thought that the iodine load may unmask hyperthyroidism in patients with multinodular goiter and subclinical Graves’ disease
- Drug-induced destructive thyroiditis
- More commonly, the cytotoxic effects of amiodarone destroy thyroid cells, resulting in a release of preformed hormone.
- Amiodarone Pulmonary Toxicity
- ↑ Rosen's 8th Edition